DALTON CHEKOKO WAMALWA

Summary

Country: Kenya

Publications

  1. pmc Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children
    Dalton C Wamalwa
    Department of Pediatrics, University of Nairobi, Nairobi, Kenya
    J Acquir Immune Defic Syndr 45:311-7. 2007
  2. pmc Prevalence of hearing loss in children following bacterial meningitis in a tertiary referral hospital
    Benson Wahome Karanja
    University of Nairobi, P, O, Box 2209 00202, KNH, Nairobi, Kenya
    BMC Res Notes 7:138. 2014
  3. pmc Mode of delivery and postpartum HIV-1 disease progression and mortality in a Kenyan cohort
    Jennifer A Unger
    Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
    BMC Pregnancy Childbirth 14:257. 2014
  4. pmc Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy
    Dalton C Wamalwa
    Department of Pediatrics, University of Nairobi, Nairobi, Kenya
    J Acquir Immune Defic Syndr 62:267-74. 2013
  5. pmc Survival benefit of early infant antiretroviral therapy is compromised when diagnosis is delayed
    Dalton Wamalwa
    Department of Paediatrics, University of Nairobi, Nairobi, Kenya
    Pediatr Infect Dis J 31:729-31. 2012
  6. pmc Evaluation of a single round polymerase chain reaction assay using dried blood spots for diagnosis of HIV-1 infection in infants in an African setting
    Bhavna H Chohan
    Department of Medical Microbiology, University of Nairobi College of Health Sciences, off Ngong Road, Nairobi, Box 19767 00202, Kenya
    BMC Pediatr 11:18. 2011
  7. pmc Medication diaries do not improve outcomes with highly active antiretroviral therapy in Kenyan children: a randomized clinical trial
    Dalton C Wamalwa
    Department of Paediatrics University of Nairobi, Nairobi, Kenya
    J Int AIDS Soc 12:8. 2009
  8. pmc Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort
    Dalton C Wamalwa
    Department of Paediatrics, University of Nairobi, Box 19676, Nairobi 00202, Kenya
    BMC Pediatr 10:33. 2010
  9. pmc Utility of total lymphocyte count as a surrogate marker for CD4 counts in HIV-1 infected children in Kenya
    Nyawira Githinji
    Department of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya
    BMC Infect Dis 11:259. 2011

Research Grants

  1. Long-term efficacy of pediatric HAART
    DALTON CHEKOKO WAMALWA; Fiscal Year: 2010

Collaborators

Detail Information

Publications9

  1. pmc Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children
    Dalton C Wamalwa
    Department of Pediatrics, University of Nairobi, Nairobi, Kenya
    J Acquir Immune Defic Syndr 45:311-7. 2007
    ....
  2. pmc Prevalence of hearing loss in children following bacterial meningitis in a tertiary referral hospital
    Benson Wahome Karanja
    University of Nairobi, P, O, Box 2209 00202, KNH, Nairobi, Kenya
    BMC Res Notes 7:138. 2014
    ..This prospective study was conducted in the audiology unit and paediatric wards of Kenyatta National Hospital, KNH...
  3. pmc Mode of delivery and postpartum HIV-1 disease progression and mortality in a Kenyan cohort
    Jennifer A Unger
    Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
    BMC Pregnancy Childbirth 14:257. 2014
    ..The purpose of this study was to assess the effect of mode of delivery on HIV-1 disease progression and postpartum mortality in a Kenyan cohort...
  4. pmc Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy
    Dalton C Wamalwa
    Department of Pediatrics, University of Nairobi, Nairobi, Kenya
    J Acquir Immune Defic Syndr 62:267-74. 2013
    ..Therefore, understanding the long-term rate of virologic failure and drug resistance during prolonged antiretroviral treatment is important for establishing treatment strategies in African pediatric cohorts...
  5. pmc Survival benefit of early infant antiretroviral therapy is compromised when diagnosis is delayed
    Dalton Wamalwa
    Department of Paediatrics, University of Nairobi, Nairobi, Kenya
    Pediatr Infect Dis J 31:729-31. 2012
    ..Early HIV-1 diagnosis with antiretroviral therapy before symptomatic disease is critical for infant survival...
  6. pmc Evaluation of a single round polymerase chain reaction assay using dried blood spots for diagnosis of HIV-1 infection in infants in an African setting
    Bhavna H Chohan
    Department of Medical Microbiology, University of Nairobi College of Health Sciences, off Ngong Road, Nairobi, Box 19767 00202, Kenya
    BMC Pediatr 11:18. 2011
    ....
  7. pmc Medication diaries do not improve outcomes with highly active antiretroviral therapy in Kenyan children: a randomized clinical trial
    Dalton C Wamalwa
    Department of Paediatrics University of Nairobi, Nairobi, Kenya
    J Int AIDS Soc 12:8. 2009
    ..abstract:..
  8. pmc Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort
    Dalton C Wamalwa
    Department of Paediatrics, University of Nairobi, Box 19676, Nairobi 00202, Kenya
    BMC Pediatr 10:33. 2010
    ..Among children, early mortality following highly active antiretroviral therapy (HAART) remains high. It is important to define correlates of mortality in order to improve outcome...
  9. pmc Utility of total lymphocyte count as a surrogate marker for CD4 counts in HIV-1 infected children in Kenya
    Nyawira Githinji
    Department of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya
    BMC Infect Dis 11:259. 2011
    ..In resource-limited settings, such as Kenya, access to CD4 testing is limited. Therefore, evaluation of less expensive laboratory diagnostics is urgently needed to diagnose immuno-suppression in children...

Research Grants1

  1. Long-term efficacy of pediatric HAART
    DALTON CHEKOKO WAMALWA; Fiscal Year: 2010
    ..This study will provide important information on effectiveness of HAART regimens being scaled up in resource-poor countries and help programs better plan for changes of drug regimens following treatment failure. ..